IMR Press / CEOG / Volume 44 / Issue 1 / DOI: 10.12891/ceog3254.2017

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Follow-up study of symptomatic submucous fibroids after hysteroscopic myomectomy
Show Less
1 Department of Obstetrics and Gynecology, Iizuka Hospital, Iizuka, Japan
Clin. Exp. Obstet. Gynecol. 2017, 44(1), 61–64; https://doi.org/10.12891/ceog3254.2017
Published: 10 February 2017
Abstract

Purpose of investigation: This study aimed to estimate the effectiveness of hysteroscopic myomectomy for symptomatic submucous uterine fibroids and to identify prognostic factors for persistent or recurrent symptoms. Materials and Methods: A total of 237 patients who underwent hysteroscopic myomectomy were divided into three groups according to the classification of the European Society for Gynaecological Endoscopy: Type 0 (n=116), Type I (n=97), and Type II (n=24). Medical records and videotape records of all patients were retrospectively reviewed. Results: Improvement of symptoms was achieved in 100% of Types 0 and I, and 66.7% of Type II. The five-year cumulative symptom-free rates after hysteroscopic myomectomy were 96.7% ± 1.9%, 87.8% ± 6.7%, and 44.5% ± 12.7% in Types 0, I, and II, respectively. The mean symptom-free periods were 46.2 ± 2.6, 47.7 ± 2.7, and 24.7 ± 6.3 months in Types 0, I, and II, respectively. Logistic regression analysis showed that co-existence of other myomas and Type II were independent prognostic factors for recurrence of symptoms. Conclusion: Type I fibroids are a good indication for hysteroscopic myomectomy. In Type II, some patients feel that their symptoms improve, but this curative effect could be temporary.
Keywords
Hysteroscopic myomectomy
Symptomatic submucous fibroid
Share
Back to top